Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis
Open Access
- 9 February 2005
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 293 (6) , 681-689
- https://doi.org/10.1001/jama.293.6.681
Abstract
Current therapy for patients with acute venous thromboembolism consists of 5 to 7 days of unfractionated heparin or low-molecular-weight heparin, overlapped with and followed by long-term oral anticoagulation with a vitamin K antagonist such as warfarin. Heparins must be given parenterally, and their administration requires considerable health care resources. Warfarin has an unpredictable dose response, interacts with many drugs, and can be affected by changes in diet; thus, continued coagulation monitoring and dose adjustment are necessary.1,2Keywords
This publication has 15 references indexed in Scilit:
- Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor XimelagatranNew England Journal of Medicine, 2003
- Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjectsEuropean Journal of Clinical Pharmacology, 2003
- Absorption, Distribution, Metabolism, and Excretion of Ximelagatran, an Oral Direct Thrombin Inhibitor, in Rats, Dogs, and HumansDrug Metabolism and Disposition, 2003
- The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding modelJournal of Thrombosis and Haemostasis, 2003
- Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug InteractionsClinical Pharmacokinetics, 2003
- A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE IJournal of Thrombosis and Haemostasis, 2003
- Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic RangeChest, 2001
- Equivalence and noninferiority trialsAmerican Heart Journal, 2000
- A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein ThrombosisNew England Journal of Medicine, 1996
- Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1992